Better Health for All

ACADIA Pharmaceuticals Inc. focuses on developing and commercializing therapies for central nervous system disorders and rare diseases, with FDA-approved treatments for Parkinson’s psychosis (NUPLAZID) and Rett syndrome (DAYBUE).

These products provide substantial health benefits, aligning with the company's mission to advance care for these conditions. However, NUPLAZID carries a boxed warning for increased mortality risk in elderly patients with dementia-related psychosis, and DAYBUE has common side effects such as diarrhea, vomiting, and weight loss. In FY2024, NUPLAZID sales, which carry the mortality risk, constituted 63.6% of total net product sales ($609.4 million out of $957.8 million). The company provides financial assistance programs like Acadia Connect, with 9 out of 10 commercially covered NUPLAZID patients paying less than $10 out-of-pocket and 100% Medicare Part D coverage. Acadia Connect also supports patients without insurance. Acadia prioritizes diversity and inclusion in clinical trials and ensures patient safety, confidentiality, and privacy. R&D expenses for FY2024 were $303.2 million, representing 31.6% of total net product sales, and the company plans to invest in clinical trials for Prader-Willi Syndrome, Alzheimer's disease psychosis, and Lewy Body Dementia Psychosis. Risk information for DAYBUE and NUPLAZID is provided, including warnings and side effects, but the DAYBUE risk information is noted as not comprehensive. The company collects Protected Health Information (PHI) and requires patient authorization for its disclosure to third parties, with privacy practices available online. Acadia Connect provides educational support and resources for patients and caregivers.

Fair Pay & Worker Respect

The CEO-to-median employee pay ratio for 2024 was 26:1, with the CEO's total compensation at $8,776,578 and the median employee pay at $340,972.

The voluntary employee turnover rate in 2023 was 10.5%, which is reported to be below U.S. and global industry averages.

Honest & Fair Business

ACADIA Pharmaceuticals has a formal whistleblower protection policy, including a hotline and web portal.

An executive transition agreement explicitly protects the right to disclose unlawful acts to governmental entities without company notification. The company has not reported any financial restatements in the past five years. Its financial statements are audited by Ernst & Young LLP, covering 100% of its units. The company's 10-K filing mentions compliance with the Foreign Corrupt Practices Act, indicating an anti-corruption policy is in place, but details on its training frequency or effectiveness metrics are not provided.

Kind to Animals

Acadia Pharmaceuticals is not certified cruelty-free.

The company employs animal testing in its pharmaceutical product development and research. While the FDA is promoting alternative testing methods that could spare thousands of animals annually, there is no specific data on the number of animals Acadia Pharmaceuticals uses in testing. The company's policy on animal testing lacks specific details on its scope and enforcement.

No War, No Weapons

The provided articles do not contain any specific data points or information relevant to ACADIA Pharmaceuticals Inc.'s involvement with arms manufacturing, military contracts, conflict facilitation, or peacebuilding initiatives.

All articles explicitly state that no data is available for the requested metrics related to the 'No War, No Weapons' value, thus precluding any scoring.

Planet-Friendly Business

ACADIA Pharmaceuticals Inc. does not publicly disclose specific quantitative data for any of the Planet-Friendly Business KPIs in the provided articles. Information regarding Scope 1, 2, and 3 emissions, SBTi-aligned targets, renewable energy use, water use, green building certifications, waste diversion rates, EU Taxonomy alignment for capital expenditure, lifecycle impact analysis, recycled to virgin material ratios, carbon offset quality, climate-positive initiatives, supply chain climate transparency, supplier SBTi targets, biodiversity efforts, deforestation policies, environmental compliance violations, environmental impact assessments, net-zero targets, TCFD alignment, climate scenario analysis, stranded assets transparency, water sourcing from stressed basins, packaging CO2 reduction, climate justice initiatives, just transition programs, or climate adaptation financing is not available for ACADIA Pharmaceuticals Inc.

The DitchCarbon score for ACADIA Pharmaceuticals Inc. is 15, which is lower than 78% of the industry average of 28, but this is a comparative score and not a direct measure for any specific KPI.

Respect for Cultures & Communities

Acadia Pharmaceuticals has established 6 formal partnerships with various organizations, including OUTbio, The Jason Foundation, Inc., Caregiver Action Network, International Rett Syndrome Foundation, Parkinson’s Foundation, and the Michael J. Fox Foundation.

There are no reported cultural appropriation incidents. The company supports organizations like the Tennessee Historical Society, which implies general charitable giving without a specific percentage of revenue donated to cultural heritage organizations. Acadia states that potential issues are thoroughly investigated with further action if necessary, and it blocks or deletes derogatory comments on social media. The company provides compulsory instructor-led and on-demand training on Diversity, Equity, Inclusion & Belonging (DEIB) topics, and Acadians are learning about microaggressions, but a completion percentage for cultural sensitivity training is not provided.

Safe & Smart Tech

Acadia Pharmaceuticals Inc. holds certifications for the EU-U.S. Data Privacy Framework, its UK Extension, and the Swiss-U.S. Data Privacy Framework, demonstrating compliance with these international data transfer mechanisms.

The company aligns its cyber risk activities with relevant regulatory requirements, including CCPA, U.S. SEC, GDPR, and NIS 2 Directive, and is subject to the investigatory and enforcement authority of the US Federal Trade Commission for Data Privacy Framework compliance. Acadia states it invests in continuous education for its teams and contributes to the development and maintenance of security policies, procedures, and training programs. It also mentions investing in advanced security measures and a vulnerability management policy, and encrypting certain data, but specific details on the scope, effectiveness, or quantitative metrics for these areas are not provided. The company experienced a data breach in February 2024, affecting personal and health information, but the specific number of individuals impacted is not disclosed, preventing a quantitative assessment of its severity.

Zero Waste & Sustainable Products

No specific, quantitative evidence was found in the provided articles for ACADIA Pharmaceuticals Inc. regarding its waste diversion rate, product recyclability, packaging sustainability, recycled content percentage, single-use plastic reduction, take-back program coverage, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability score, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging to product ratio, waste reduction targets, supplier waste requirements, or customer waste education. While one article mentioned a take-back program for packaging materials for a specific product (DAYBUE®),

it did not provide a percentage of products covered or a breakdown of packaging materials by weight/volume to assess sustainability. Another article mentioned a commitment to "green chemistry" and a LEED Gold certified building, but these are not direct, quantifiable metrics for the specified KPIs.